Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 78 Melanoma 62 Squamous Cell Carcinoma of Head and Neck 46 Breast Neoplasms 37 Neoplasm Metastasis 34 Parkinson Disease 4, Autosomal Dominant Lewy Body 32 Carcinoma, Renal Cell 30 Lung Neoplasms 29 Colorectal Neoplasms 29 Neoplasms 25 Ovarian Neoplasms 24 Triple Negative Breast Neoplasms 22 Head and Neck Neoplasms 22 Stomach Neoplasms 17 Urinary Bladder Neoplasms 16 Endometrial Neoplasms 15 Carcinoma, Transitional Cell 15 Pancreatic Neoplasms 13 Prostatic Neoplasms 11 Uterine Cervical Neoplasms 10 Sarcoma 10 Esophageal Neoplasms 10 Small Cell Lung Carcinoma 9 Recurrence 9 Glioblastoma 8 Fallopian Tube Neoplasms 8 Carcinoma, Squamous Cell 8 Carcinoma 8 Skin Neoplasms 7 Oropharyngeal Neoplasms 7

Interventions

pembrolizumab 1 liposomal doxorubicin 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Adenoviridae Infections × pembrolizumab × Clear all

NCT05271318 2026-05-05

PROTA

TILT Biotherapeutics Ltd.

Phase 1/2 Active not recruiting

Adenoviridae Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡